The MOPETT Trial took sub-massive PE patients and randomized them to half-dose tPA vs. standard care. No bleeds in either group. 41% ARR of pulmonary hypertension at 28 months.
Study Description from the Author
Does this change your game?
A new trial using a similar protocol showed benefit without complications (Clinical Cardiology Volume 37, Issue 2, pages 78–82, February 2014)
Latest posts by Scott Weingart (see all)
- Podcast 193 – Emergency Medicine is a Failed Paradigm - February 20, 2017
- EMCrit Wee – The Golden Fleece, the Golden Hour, and the Golden Rule by Ashley Liebig - February 15, 2017
- Choose the 2017 EEM Fellowship Winner - February 7, 2017